These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30669162)

  • 1. Correlation Between Violence and Antipsychotic Dosage in Schizophrenia: A Secondary Analysis of The Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) Dataset.
    Tasmim S; Kolla NJ; Dada O; Bani-Fatemi A; De Luca V
    Pharmacopsychiatry; 2019 Sep; 52(5):217-221. PubMed ID: 30669162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of Future Violence in People Being Treated for Schizophrenia.
    Buchanan A; Sint K; Swanson J; Rosenheck R
    Am J Psychiatry; 2019 Sep; 176(9):694-701. PubMed ID: 31014102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset.
    Witt K; Hawton K; Fazel S
    Schizophr Res; 2014 Apr; 154(1-3):61-7. PubMed ID: 24581550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polygenic risk score prediction of antipsychotic dosage in schizophrenia.
    Hettige NC; Cole CB; Khalid S; De Luca V
    Schizophr Res; 2016 Feb; 170(2-3):265-70. PubMed ID: 26778674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate gene analysis of pharmacodynamic targets for antipsychotic dosage.
    Hettige NC; de Moraes GH; Kennedy JL; De Luca V
    Pharmacogenomics; 2016 Feb; 17(3):199-208. PubMed ID: 26780210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.
    Tani H; Takasu S; Uchida H; Suzuki T; Mimura M; Takeuchi H
    Neuropsychopharmacology; 2020 Apr; 45(5):887-901. PubMed ID: 31770770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.
    Ozzoude M; Nakajima S; Plitman E; Chung JK; Kim J; Iwata Y; Caravaggio F; Takeuchi H; Uchida H; Graff-Guerrero A; Gerretsen P
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():207-213. PubMed ID: 30172739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A national study of violent behavior in persons with schizophrenia.
    Swanson JW; Swartz MS; Van Dorn RA; Elbogen EB; Wagner HR; Rosenheck RA; Stroup TS; McEvoy JP; Lieberman JA
    Arch Gen Psychiatry; 2006 May; 63(5):490-9. PubMed ID: 16651506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Schizophrenia and violence, incidence and risk factors: a Tunisian sample].
    Ellouze F; Ayedi S; Masmoudi S; Bakri L; Chérif W; Zramdini R; Largueche M; Amri H; Ben Abla T; M'rad MF
    Encephale; 2009 Sep; 35(4):347-52. PubMed ID: 19748371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study.
    Koga AT; Strauss J; Zai C; Remington G; De Luca V
    J Neural Transm (Vienna); 2016 Mar; 123(3):329-38. PubMed ID: 26821981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients.
    Mohr P; Knytl P; Voráčková V; Bravermanová A; Melicher T
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.
    Fervaha G; Agid O; Takeuchi H; Foussias G; Remington G
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1078-85. PubMed ID: 24726579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.
    Volavka J; Van Dorn RA; Citrome L; Kahn RS; Fleischhacker WW; Czobor P
    Eur Psychiatry; 2016 Jan; 31():13-9. PubMed ID: 26657597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.
    Swanson JW; Swartz MS; Elbogen EB
    Schizophr Bull; 2004; 30(1):3-20. PubMed ID: 15176758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: an analysis of the CATIE dataset.
    Dunayevich E; Chen CY; Marder SR; Rabinowitz J
    Eur Neuropsychopharmacol; 2014 Oct; 24(10):1615-21. PubMed ID: 25172269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.